Back to Search
SURESH RAMALINGAM, MD
MD
Medical Oncology Physician
NPI: 1457326936IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
59945(GA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
PMID 19096314·J Thorac Oncol·2009
3-trial
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
PMID 19342473·Oncologist·2009
6-review
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
PMID 18512224·Cancer·2008
3-trial
Recent advances in the treatment of malignant pleural mesothelioma.
PMID 18758312·J Thorac Oncol·2008
6-review
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
PMID 18165641·J Clin Oncol·2008
2-rct
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
PMID 18519777·Clin Cancer Res·2008
3-trial
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
PMID 17510206·Clin Cancer Res·2007
3-trial
Recent advances in targeted therapy for non-small cell lung cancer.
PMID 17227238·Expert Opin Ther Targets·2007
6-review
First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
PMID 16384540·Clin Lung Cancer·2005
6-review
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
PMID 19621389·Int J Cancer·2010
8-other
Targeted manipulation of mammalian genomes using designed zinc finger nucleases.
PMID 19635463·Biochem Biophys Res Commun·2009
7-preclinical
Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium.
PMID 19550249·J Thorac Oncol·2009
8-other
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
PMID 19362942·Clin Lung Cancer·2009
6-review
Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all.
PMID 19470911·J Clin Oncol·2009
8-other
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.
PMID 19483468·Cancer Biol Ther·2009
8-other
Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.
PMID 19658185·Cancer·2009
6-review
Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism.
PMID 19445940·Gastroenterology·2009
4-observational
Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells.
PMID 19671677·Mol Cancer Res·2009
8-other
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
PMID 19675541·Clin Pharmacol Ther·2009
3-trial
The role of cetuximab in the management of non-small-cell lung cancer.
PMID 19632939·Clin Lung Cancer·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1365 CLIFTON RD NE, WINSHIP CANCER INSTITUTE
ATLANTA, GA 30322 - Phone
- (404) 778-5961
Quick Facts
- NPI
- 1457326936
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile